Chief Scientific Officer & CEO @LumaCyte | Innovative Scientist and Entrepreneur | Analytical Expert | Biotechnology Professional
Greater Charlottesville Area
Joined December 2022
- Tweets190
- Following700
- Followers224
- Likes164
Sean Hart, PhD retweeted
New in @CD_AACR! 👏
Dr. Ruth Scherz-Shouval and colleagues unravel a pathway of CAF-mediated suppression of NK cells in #BreastCancer, opening possible avenues for new biomarkers and strategies for immune-based therapies. #TumorMicroenviromment
🔗 bit.ly/3ZdI9dx
Fascinating subject - also important to look at chemosensing and the host response of mammalian cells to bacteria.
Why do bacteria talk to each other?
Julie Valastyan (Bassler Lab, @Princeton) studies cell-cell communication to understand how bacteria behave, in hopes that scientists can one day design new therapies to combat bacterial infections. 🧫🧠
This is what makes a company great - purpose, passion, and relentless pursuit of excellence!
A chondrocyte cell experiencing laser optical force in fluid flow measured with Laser Force Cytology (LFC). LFC measures 2 dozen biophysical and biochemical parameters for every cell in real time. It's used for quantitative predictive cellular analytics throughout biomanufacturing of vaccines, cell, and gene therapies.
lumacyte.com
Sean Hart, PhD retweeted
A crawling cell videoed through a microscope. #CellBiology
Interesting and worrying at the same time… AI draws on existing knowledge and by definition peer review of papers is new work, so how can AI ‘judge’ appropriately?
AI is transforming peer review — and many scientists are worried
Artificial intelligence software is increasingly involved in reviewing papers, provoking interest and unease. nature.com/articles/d41586-0… @Nature
Sean Hart, PhD retweeted
A paralysed man can stand on his own after receiving an injection of neural stem cells to treat his spinal cord injury. The Japanese man was one of four individuals in a first-of-its-kind trial that used reprogrammed stem cells to treat people who are fully paralysed. nature.com/articles/d41586-0… @Nature
Sean Hart, PhD retweeted
#MEDIA: The European Commission has approved our #CARTcelltherapy for patients living with relapsed or refractory follicular lymphoma (FL). Read more: bit.ly/3Fwuuar
Preparing for CAR T cell therapy: A roadmap for patient selection, bridging therapies, and lymphodepletion. This review highlights the critical steps to optimize outcomes for B-cell malignancies.
A must-read for oncology cell therapy! Nature Review #CARTCellTherapy #OncologyResearch
nature.com/articles/s41571-0…
Looking forward to the ISCT 2025 meeting!
Announcing our inaugural Keynote Speaker for ISCT 2025!
Join us on the evening of Friday, May 9th, as Dr. Fred Applebaum discusses the status of our sector and projects into its future.
#ISCT2025
Learn more at isct2025.com
Sean Hart, PhD retweeted
Beyond Viability: Healthier Cells, Better Therapies.
What if cell health wasn’t just viable, but optimal? Discover how advanced technologies are reshaping cell therapy by redefining viability. Dive into the future of healthier, more robust cells: lumacyte.com/applications/ce…
#CellTherapy #Innovation #CellHealth #FutureOfMedicine #BiotechBreakthrough
Sean Hart, PhD retweeted
Join the LumaCyte Team at Advanced Therapies Week next week in Dallas, Texas. Discover groundbreaking innovations and network with industry leaders at the premier event for advanced therapies. Don’t miss your chance to explore cutting-edge research, gain insights from the brightest minds, and shape the future of healthcare. Visit us at Booth 448. Schedule a meeting with LumaCyte.
lumacyte.com/schedule-a-meet…
#AdvancedTherapiesWeek #HealthcareInnovation #LumaCyte #FutureOfMedicine #Biotech #MedicalResearch #CuttingEdgeScience #Dallas2025 #AdvancedTherapies
Excited to be attending ISCT in Vancouver and really enjoyed participating in the panel discussion on PAT for cell therapy this morning! Thank you @ISCTglobal!
#ISCT2024 has officially begun! We are excited to reunite our global cell and gene therapy community in Vancouver for four days jam packed with cutting edge content!
Amazing to work with such talented people - we are excited to continue driving innovation and advanced analytics with ATCC.
Presented brand new @LumaCyte data @BEBPA US Bioassay Conference in Long Beach, CA this past Tuesday. We showed initial data correlating Laser Force Cytology measurements of PBMC with the killing efficiency of CAR T products - a very important step to improve the efficiency of manufacturing for this important cell therapy!
As part of a recent study co-led by HMS scientists, a novel #GeneTherapy was tested, restoring the hearing of five children who were born with a form of genetic #deafness.
#GeneTherapy #CGT hms.harvard.edu/news/experim…
An 11-year-old born with a genetic form of hearing loss experienced restored hearing thanks to a new #GeneTherapy. This dual adeno-associated viral vector-based therapy could be a game-changer, opening up new therapeutic possibilities. genengnews.com/topics/transl…
